Stirling Products Limited (ASX:STI) Gets Approval For TB And HIV Treatment “Immunoxel” In South Africa
Australian healthcare company Stirling Products Limited (ASX:STI) is pleased to announce another milestone in the expansion of the licensed (pending joint venture approval) botanical products to markets outside of Ukraine. Immunoxel (Dzherelo) has been granted approval in South Africa. This approval will allow immediate sales of the phytoconcentrate as an immune adjuvant for TB and HIV treatment.
More: continued here
Filed under: HIV / AIDS on June 1st, 2009
You must be logged in to post a comment.